Zuellig Pharma, a prominent provider of healthcare solutions in Asia, has revealed an extension of its collaboration in commercialization with Karo Healthcare ("Karo"). Established in 1987, Karo is a prominent European consumer healthcare firm based in Stockholm, Sweden, with its products accessible in over 90 nations.
Under the terms of the updated agreement, Zuellig Pharma has been designated as the sole commercialization collaborator for Karo's over-the-counter (OTC) brand Lamisil, utilized for fungal infection treatment. This partnership extends across key markets including Hong Kong, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Vietnam. Leveraging its extensive coverage among healthcare professionals and retail pharmacies in the region, ZP Therapeutics, the commercial arm of Zuellig Pharma, will lead this collaborative effort.
Zuellig Pharma has had a strong commercialization partnership with Karo since 2019 for its product portfolio in the Philippines, Vietnam, Singapore and Indonesia. "We are excited to work with Karo to expand access and availability of its products. As an integrated healthcare solutions company, this partnership will also play a key role in the strengthening of Zuellig Pharma's consumer health portfolio as we grow in key markets such as Korea and Taiwan", said John Graham, Group CEO, Zuellig Pharma. "I'm confident that ZP Therapeutics' extensive partner network and proven commercial expertise will be critical in facilitating greater access for in-demand consumer healthcare products in Asia".
Zuellig Pharma stands as a premier healthcare solutions provider in Asia, dedicated to enhancing healthcare accessibility within the communities we serve. Our commitment extends to delivering top-tier distribution, digital, and commercial services to meet the evolving healthcare demands in this region. Originating a century ago, our company has expanded into a multibillion-dollar enterprise spanning across 16 markets, boasting a workforce of over 12,000 individuals. Our dedicated personnel cater to the needs of over 200,000 medical facilities and collaborate with more than 450 clients, including the foremost pharmaceutical entities globally.
ZP Therapeutics, a segment within Zuellig Pharma, is recognized as the preferred commercialization partner within the healthcare sector, maintaining offices in 13 Asian countries and employing over 2,500 professionals. Serving as a driving force in enhancing patient experiences and healthcare results through exemplary commercial practices, resilient market capabilities, and unwavering ethical standards, ZP Therapeutics stands as a dependable ally in broadening patient reach and introducing groundbreaking innovations to the healthcare landscape.